Overview

This trial is active, not recruiting.

Condition dengue fever
Treatments takeda's tetravalent dengue vaccine candidate (tdv), takeda's high-dose tetravalent dengue vaccine candidate (hd-tdv)
Phase phase 2
Sponsor Takeda
Start date June 2015
End date August 2017
Trial size 400 participants
Trial identifier NCT02425098, DEN-205, U1111-1166-8884

Summary

The purpose of this study is to assess the post-vaccination neutralizing antibody response against each dengue serotype by treatment arm.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose prevention
Arm
(Experimental)
High-dose Tetravalent Dengue Vaccine Candidate [HD-TDV], 0.5 mL, subcutaneous injection on Day 1.
takeda's high-dose tetravalent dengue vaccine candidate (hd-tdv)
High-dose TDV subcutaneous injection
(Experimental)
Tetravalent Dengue Vaccine Candidate [TDV], 0.5 mL, subcutaneous injection on Day 1.
takeda's tetravalent dengue vaccine candidate (tdv)
TDV subcutaneous injection

Primary Outcomes

Measure
Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the Four DENV Serotypes
time frame: Up to 12 Months
Percentage of Participants Seropositive to Each of the Four DENV Serotypes
time frame: Up to 12 Months

Secondary Outcomes

Measure
Percentage of Participants with Solicited Local (Injection Site) Adverse Events (AEs)
time frame: Up to Day 7
Percentage of Participants with Solicited Systemic Adverse Events (AEs)
time frame: Up to Day 14
Percentage of Participants with Any Unsolicited Adverse Events (AEs)
time frame: Up to Day 28 after vaccination
Percentage of Participants with Serious Adverse Events (SAEs)
time frame: Up to 12 Months
Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the Four DENV Serotypes Assessed by Dengue Baseline Seropositivity (MNT) Status
time frame: Up to 12 Months
Percentage of Participants Seropositive to Each of the Four DENV Serotypes Assessed by Dengue Baseline Seropositivity (MNT) Status
time frame: Up to 12 Months
Percentage of Participants with Vaccine Viremia for each of the Four Dengue Serotypes
time frame: Up to Day 30
Duration of Vaccine Viremia for each of the Four Dengue Serotypes
time frame: Up to Day 30
Level of Vaccine Viremia for each of the Four Dengue Serotypes
time frame: Up to Day 30

Eligibility Criteria

Male or female participants from 21 years up to 45 years old.

Inclusion Criteria: 1. Participant signs and dates a written informed consent form where applicable, and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to local regulatory requirements. 2. Is aged 21 to 45 years of age, inclusive. 3. Is in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the Investigator. 4. Can comply with trial procedures and are available for the duration of follow-up. 5. Has self-declared as never having been vaccinated against Yellow Fever or Japanese Encephalitis Virus. Exclusion Criteria: 1. Has febrile illness (temperature ≥38°C or ≥100.4°F) or moderate or severe acute illness or infection at the time of enrollment. 2. Has history or any illness that, in the opinion of the Investigator, might interfere with the results of the trial or pose an additional risk to the participant due to participation in the trial, including but not limited to: 1. Known hypersensitivity or allergy to any of the vaccine components. 2. Female participants who are pregnant or breastfeeding. 3. Individuals with any serious chronic or progressive disease according to judgment of the Investigator (e.g. neoplasm, insulin-dependent diabetes, cardiac, renal or hepatic disease, neurologic or seizure disorder or Guillain-Barré syndrome). 4. Known or suspected impairment/alteration of immune function, including: - i. Chronic use of oral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (Month 0) (use of inhaled, intranasal, or topical corticosteroids is allowed). - ii. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥ 2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (Month 0). - iii. Administration of immunoglobulins and/or any blood products within the 3 months prior to Day 1 (Month 0) or planned administration during the trial. - iv. Receipt of immunostimulants within 60 days prior to Day 1(Month 0). - v. Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within 6 months prior to Day 1 (Month 0). - vi. Human immunodeficiency virus (HIV) infection and HIV-related diseases. - vii. Hepatitis C virus (HCV) infection. - viii. Genetic immunodeficiency. 3. Has received any other vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to Day 1 (Month 0) or planning to receive any vaccine within 28 days after Day 1 (Month 0). 4. Has participated in any clinical trial with another investigational product 30 days prior to Day 1 (Month 0) or intent to participate in another clinical trial at any time during the conduct of this trial. 5. Has previously participated in any clinical trial of a dengue candidate vaccine, or previous receipt of a dengue vaccine. 6. Is first-degree relative of individuals involved in trial conduct. 7. For females of childbearing potential who are sexually active, and who have not used any of the acceptable contraceptive methods for at least 2 months prior to Day 1 (Month 0). 1. Of childbearing potential is defined as status post onset of menarche and not meeting any of the following conditions: bilateral tubal ligation (at least 1 year previously), bilateral oophorectomy (at least 1 year previously) or hysterectomy. 2. Acceptable birth control methods are defined as one or more of the following: - i. Hormonal contraceptive (such as oral, injection, transdermal patch, implant, cervical ring). - ii. Barrier (condom with spermicide or diaphragm with spermicide) each and every time during intercourse. - iii. Intrauterine device (IUD). - iv. Monogamous relationship with vasectomized partner (partner must have been vasectomized for at least six months prior to Day 1 [Month 0]). 8. Females of childbearing potential who are sexually active, and who refuse to use an acceptable contraceptive method from signing the informed consent up to 6 weeks post-vaccination.

Additional Information

Official title A Phase II, Double-Blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of a Tetravalent Dengue Vaccine With Two Different Serotype 2 Potencies in an Adult Population in Singapore
Description The vaccine being tested in this study is Takeda's Tetravalent Dengue Vaccine Candidate (TDV). TDV is being tested to protect people against dengue fever. This study will look at safety and the amount of antibodies to dengue fever formed in people who are administered a high-dose of TDV (HD-TDV) compared to TDV. The study will enroll approximately 400 patients. Before being assigned to a treatment group participants will be screened for previous exposure to the dengue virus. Dengue naïve and previously exposed participants will then be randomly assigned (by chance) to one of the two treatment groups—which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need): - HD-TDV 0.5 mL subcutaneous injection - TDV 0.5 mL subcutaneous injection All participants will receive a single injection on Day 1. Participants will be asked to record any symptoms that may be related to the vaccine or the injection site in a diary card for 28 days after vaccination. This multi-center trial will be conducted in Singapore. The overall time to participate in this study is 12 months. Participants will make multiple visits to the clinic, including a final visit 1 year after receiving their dose of TDV.
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Takeda.